X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DR. DATSONS LABS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DR. DATSONS LABS GLENMARK PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 23.8 -10.9 - View Chart
P/BV x 3.2 0.2 1,993.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
GLENMARK PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs930126 740.4%   
Low Rs51731 1,674.4%   
Sales per share (Unadj.) Rs322.6133.0 242.6%  
Earnings per share (Unadj.) Rs28.50.2 18,790.8%  
Cash flow per share (Unadj.) Rs39.26.6 593.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0128.8 142.1%  
Shares outstanding (eoy) m282.1731.66 891.3%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x2.20.6 381.3%   
Avg P/E ratio x25.4516.1 4.9%  
P/CF ratio (eoy) x18.511.8 155.9%  
Price / Book Value ratio x4.00.6 650.9%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2062,477 8,242.8%   
No. of employees `00013.7NA-   
Total wages/salary Rs m18,71856 33,425.7%   
Avg. sales/employee Rs Th6,636.8NM-  
Avg. wages/employee Rs Th1,364.7NM-  
Avg. net profit/employee Rs Th586.1NM-  
INCOME DATA
Net Sales Rs m91,0314,211 2,162.0%  
Other income Rs m91479 1,161.4%   
Total revenues Rs m91,9454,289 2,143.6%   
Gross profit Rs m16,154569 2,841.0%  
Depreciation Rs m3,019204 1,476.9%   
Interest Rs m2,856430 663.8%   
Profit before tax Rs m11,19313 88,136.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1556 51,714.8%   
Profit after tax Rs m8,0395 167,472.9%  
Gross profit margin %17.713.5 131.4%  
Effective tax rate %28.248.0 58.7%   
Net profit margin %8.80.1 7,746.2%  
BALANCE SHEET DATA
Current assets Rs m69,8876,852 1,020.0%   
Current liabilities Rs m32,8796,711 490.0%   
Net working cap to sales %40.73.3 1,214.0%  
Current ratio x2.11.0 208.2%  
Inventory Days Days81161 50.6%  
Debtors Days Days93318 29.4%  
Net fixed assets Rs m28,8923,673 786.6%   
Share capital Rs m282317 89.1%   
"Free" reserves Rs m51,3533,761 1,365.4%   
Net worth Rs m51,6354,078 1,266.3%   
Long term debt Rs m41,4181,671 2,478.9%   
Total assets Rs m125,95412,633 997.1%  
Interest coverage x4.91.0 477.9%   
Debt to equity ratio x0.80.4 195.8%  
Sales to assets ratio x0.70.3 216.8%   
Return on assets %8.63.4 251.2%  
Return on equity %15.60.1 13,225.0%  
Return on capital %15.17.7 196.8%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m36,317964 3,767.3%   
Fx outflow Rs m9,720607 1,601.0%   
Net fx Rs m26,598357 7,452.4%   
CASH FLOW
From Operations Rs m16,4811,345 1,225.5%  
From Investments Rs m-10,133-2,256 449.3%  
From Financial Activity Rs m-4,685-1,200 390.5%  
Net Cashflow Rs m1,770-2,111 -83.9%  

Share Holding

Indian Promoters % 48.3 4.5 1,066.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 1.4 2,548.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 94.1 11.2%  
Shareholders   56,727 20,807 272.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 132 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed buying interest during the closing hours and ended the day in green.

Related Views on News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 15, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS